Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer

被引:252
作者
Sadeghi, Navid [2 ]
Abbruzzese, James L.
Yeung, Sai-Ching J. [3 ]
Hassan, Manal
Li, Donghui [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 426, Houston, TX 77030 USA
[2] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA
[3] Univ Texas Houston, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
关键词
CELL-CYCLE ARREST; BREAST-CANCER; ANTIDIABETIC DRUG; HEPATOCELLULAR-CARCINOMA; IN-VITRO; RISK; GROWTH; INSULIN; AMPK; METAANALYSIS;
D O I
10.1158/1078-0432.CCR-11-2994
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Accumulating evidence suggests that metformin has antitumor activity. The aim of this study was to determine whether metformin use has a survival benefit in patients with pancreatic cancer. Experimental Design: We conducted a retrospective study of patients with diabetes and pancreatic cancer treated at The University of Texas MD Anderson Cancer Center (Houston, TX). Information on diabetes history, including treatment modalities and clinical outcome of pancreatic cancer, was collected using personal interviews and medical record review. Survival analysis was carried out using a Kaplan-Meier plot, log-rank test, and Cox proportional hazards regression models. Results: Among the 302 patients identified, there were no significant differences in demographic or major clinical characteristics between the patients who had received metformin (n = 117) and those who had not (n = 185). The 2-year survival rate was 30.1% for the metformin group and 15.4% for the non-metformin group (P = 0.004; chi(2) test). The median overall survival time was 15.2 months for the metformin group, and 11.1 months for the non-metformin group (P = 0.004, log-rank test). Metformin users had a 32% lower risk of death; the HR (95% confidence interval) was 0.68 (0.52-0.89) in a univariate model (P = 0.004), 0.64 (0.48-0.86) after adjusting for other clinical predictors (P = 0.003), and 0.62 (0.44-0.87) after excluding insulin users (P = 0.006). Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only. Conclusions: Our finding that metformin use was associated with improved outcome of patients with diabetes and pancreatic cancer should be confirmed in independent studies. Future research should prospectively evaluate metformin as a supplemental therapy in this population. Clin Cancer Res; 18(10); 2905-12. (C)2012 AACR.
引用
收藏
页码:2905 / 2912
页数:8
相关论文
共 44 条
[1]   Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro [J].
Alimova, Irina N. ;
Liu, Bolin ;
Fan, Zeying ;
Edgerton, Susan M. ;
Dillon, Thomas ;
Lind, Stuart E. ;
Thor, Ann D. .
CELL CYCLE, 2009, 8 (06) :909-915
[2]   Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Berstein, LM ;
Egormin, PA ;
Piskunova, TS ;
Popovich, IG ;
Zabezhinski, MA ;
Kovalenko, IG ;
Poroshina, TE ;
Semenchenko, AV ;
Provinciali, M ;
Re, F ;
Franceschi, C .
EXPERIMENTAL GERONTOLOGY, 2005, 40 (8-9) :685-693
[3]  
[Anonymous], 2011, Cancer Facts and Figures 2011
[4]   The complexities of obesity and diabetes with the development and progressin of pancreatic cancer [J].
Bao, Bin ;
Wang, Zhiwei ;
Li, Yiwei ;
Kong, Dejuan ;
Ali, Shadan ;
Banerjee, Sanjeev ;
Ahmad, Aamir ;
Sarkar, Fazlul H. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1815 (02) :135-146
[5]   The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level [J].
Ben Sahra, I. ;
Laurent, K. ;
Loubat, A. ;
Giorgetti-Peraldi, S. ;
Colosetti, P. ;
Auberger, P. ;
Tanti, J. F. ;
Le Marchand-Brustel, Y. ;
Bost, F. .
ONCOGENE, 2008, 27 (25) :3576-3586
[6]   Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1 [J].
Ben Sahra, Isaam ;
Regazzetti, Claire ;
Robert, Guillaume ;
Laurent, Kathiane ;
Le Marchand-Brustel, Yannick ;
Auberger, Patrick ;
Tanti, Jean-Francois ;
Giorgetti-Peraldi, Sophie ;
Bost, Frederic .
CANCER RESEARCH, 2011, 71 (13) :4366-4372
[7]   Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? [J].
Ben Sahra, Issam ;
Le Marchand-Brustel, Yannick ;
Tanti, Jean-Francois ;
Bost, Frederic .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) :1092-1099
[8]   Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer [J].
Bodmer, Michael ;
Meier, Christian ;
Krahenbuehl, Stephan ;
Jick, Susan S. ;
Meier, Christoph R. .
DIABETES CARE, 2010, 33 (06) :1304-1308
[9]   Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].
Bowker, SL ;
Majumdar, SR ;
Veugelers, P ;
Johnson, JA .
DIABETES CARE, 2006, 29 (02) :254-258
[10]   Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth [J].
Buzzai, Monica ;
Jones, Russell G. ;
Amaravadi, Ravi K. ;
Lum, Julian J. ;
DeBerardinis, Ralph J. ;
Zhao, Fangping ;
Viollet, Benoit ;
Thompson, Craig B. .
CANCER RESEARCH, 2007, 67 (14) :6745-6752